168 related articles for article (PubMed ID: 16310776)
1. Identification of multiple allosteric sites on the M1 muscarinic acetylcholine receptor.
Espinoza-Fonseca LM; Trujillo-Ferrara JG
FEBS Lett; 2005 Dec; 579(30):6726-32. PubMed ID: 16310776
[TBL] [Abstract][Full Text] [Related]
2. The existence of a second allosteric site on the M1 muscarinic acetylcholine receptor and its implications for drug design.
Espinoza-Fonseca LM; Trujillo-Ferrara JG
Bioorg Med Chem Lett; 2006 Mar; 16(5):1217-20. PubMed ID: 16364641
[TBL] [Abstract][Full Text] [Related]
3. The M1 muscarinic receptor allosteric agonists AC-42 and 1-[1'-(2-methylbenzyl)-1,4'-bipiperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one bind to a unique site distinct from the acetylcholine orthosteric site.
Jacobson MA; Kreatsoulas C; Pascarella DM; O'Brien JA; Sur C
Mol Pharmacol; 2010 Oct; 78(4):648-57. PubMed ID: 20660086
[TBL] [Abstract][Full Text] [Related]
4. Structure and dynamics of the full-length M1 muscarinic acetylcholine receptor studied by molecular dynamics simulations.
Espinoza-Fonseca LM; Pedretti A; Vistoli G
Arch Biochem Biophys; 2008 Jan; 469(1):142-50. PubMed ID: 17935687
[TBL] [Abstract][Full Text] [Related]
5. The predicted 3D structures of the human M1 muscarinic acetylcholine receptor with agonist or antagonist bound.
Peng JY; Vaidehi N; Hall SE; Goddard WA
ChemMedChem; 2006 Aug; 1(8):878-90. PubMed ID: 16902941
[TBL] [Abstract][Full Text] [Related]
6. Identification of various allosteric interaction sites on M1 muscarinic receptor using 125I-Met35-oxidized muscarinic toxin 7.
Fruchart-Gaillard C; Mourier G; Marquer C; Ménez A; Servent D
Mol Pharmacol; 2006 May; 69(5):1641-51. PubMed ID: 16439611
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and pharmacological profiling of analogues of benzyl quinolone carboxylic acid (BQCA) as allosteric modulators of the M1 muscarinic receptor.
Mistry SN; Valant C; Sexton PM; Capuano B; Christopoulos A; Scammells PJ
J Med Chem; 2013 Jun; 56(12):5151-72. PubMed ID: 23718562
[TBL] [Abstract][Full Text] [Related]
8. Antagonist binding in the rat muscarinic receptor A study by docking and X-ray crystallography.
Tanczos AC; Palmer RA; Potter BS; Saldanha JW; Howlin BJ
Comput Biol Chem; 2004 Dec; 28(5-6):375-85. PubMed ID: 15556478
[TBL] [Abstract][Full Text] [Related]
9. Expanding GPCR homology model binding sites via a balloon potential: A molecular dynamics refinement approach.
Kimura SR; Tebben AJ; Langley DR
Proteins; 2008 Jun; 71(4):1919-29. PubMed ID: 18175323
[TBL] [Abstract][Full Text] [Related]
10. Allosteric binding sites on muscarinic acetylcholine receptors.
Wess J
Mol Pharmacol; 2005 Dec; 68(6):1506-9. PubMed ID: 16183853
[TBL] [Abstract][Full Text] [Related]
11. Interaction studies of multiple binding sites on m4 muscarinic acetylcholine receptors.
Lanzafame AA; Sexton PM; Christopoulos A
Mol Pharmacol; 2006 Aug; 70(2):736-46. PubMed ID: 16709648
[TBL] [Abstract][Full Text] [Related]
12. Enantiomeric N-methyl-4-piperidyl benzilates as muscarinic receptor ligands: Radioligand binding studies and docking studies to models of the three muscarinic receptors M1, M2 and M3.
Selent J; Brandt W; Pamperin D; Göber B
Bioorg Med Chem; 2006 Mar; 14(6):1729-36. PubMed ID: 16290166
[TBL] [Abstract][Full Text] [Related]
13. Crystal structures of the M1 and M4 muscarinic acetylcholine receptors.
Thal DM; Sun B; Feng D; Nawaratne V; Leach K; Felder CC; Bures MG; Evans DA; Weis WI; Bachhawat P; Kobilka TS; Sexton PM; Kobilka BK; Christopoulos A
Nature; 2016 Mar; 531(7594):335-40. PubMed ID: 26958838
[TBL] [Abstract][Full Text] [Related]
14. Multiple allosteric sites on muscarinic receptors.
Birdsall NJ; Lazareno S; Popham A; Saldanha J
Life Sci; 2001 Apr; 68(22-23):2517-24. PubMed ID: 11392621
[TBL] [Abstract][Full Text] [Related]
15. Long-term changes in the muscarinic M1 receptor induced by instantaneous formation of wash-resistant xanomeline-receptor complex.
De Lorme KC; Grant MK; Noetzel MJ; Polson SB; El-Fakahany EE
J Pharmacol Exp Ther; 2007 Dec; 323(3):868-76. PubMed ID: 17855477
[TBL] [Abstract][Full Text] [Related]
16. Novel M(1) allosteric ligands: a patent review.
Kuduk SD; Beshore DC
Expert Opin Ther Pat; 2012 Dec; 22(12):1385-98. PubMed ID: 23092292
[TBL] [Abstract][Full Text] [Related]
17. Exploration of the orthosteric/allosteric interface in human M1 muscarinic receptors by bitopic fluorescent ligands.
Daval SB; Kellenberger E; Bonnet D; Utard V; Galzi JL; Ilien B
Mol Pharmacol; 2013 Jul; 84(1):71-85. PubMed ID: 23604140
[TBL] [Abstract][Full Text] [Related]
18. Cholinergic nicotinic receptors: competitive ligands, allosteric modulators, and their potential applications.
Romanelli MN; Gualtieri F
Med Res Rev; 2003 Jul; 23(4):393-426. PubMed ID: 12710018
[TBL] [Abstract][Full Text] [Related]
19. Fluorescent pirenzepine derivatives as potential bitopic ligands of the human M1 muscarinic receptor.
Tahtaoui C; Parrot I; Klotz P; Guillier F; Galzi JL; Hibert M; Ilien B
J Med Chem; 2004 Aug; 47(17):4300-15. PubMed ID: 15294002
[TBL] [Abstract][Full Text] [Related]
20. Accelerated structure-based design of chemically diverse allosteric modulators of a muscarinic G protein-coupled receptor.
Miao Y; Goldfeld DA; Moo EV; Sexton PM; Christopoulos A; McCammon JA; Valant C
Proc Natl Acad Sci U S A; 2016 Sep; 113(38):E5675-84. PubMed ID: 27601651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
